Hefei Lifeon Pharmaceutical Hits Day Low Amid Price Pressure at CNY 17.75

Hefei Lifeon Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 9.99% on July 17, 2026. The stock reached an intraday low of CNY 17.75, reflecting ongoing challenges in its performance metrics. Over the past year, the company has reported a negative return of 12.06%, contrasting sharply with the China Shanghai Composite's positive performance of 7.03% during the same period. In terms of longer-term performance, Hefei Lifeon has faced difficulties, with a three-year decline of 26.34%, while the broader market index has gained 17.28%. The company's net sales have decreased at an annual rate of 4.87%, and operating profit has also seen a decline of 2.41% over the last five years. Financially, Hefei Lifeon holds a market capitalization of CNY 2,624 million and a price-to-earnings ratio of 16.00. The company’s return on equity stands at 8.63%, and it has a dividend yield of 2.18%. Despite these metrics, the stock's performance has consistently lagged behind the broader market trends.